AiMorphous Health

AiMorphous Health is a Swiss medtech startup founded in 2022 that specializes in the development of AI-powered blood diagnostic technology. The company focuses on creating disruptive diagnostic tools engineered to analyze blood samples using advanced machine learning models and proprietary biomarker systems. By identifying subtle patterns and early biomarkers that often elude traditional diagnostic methods, their technology aims to monitor and predict the risks of thrombosis and bleeding. This approach is designed to detect cryptic biological activities, including those related to inflammaging, providing clinicians with actionable insights to enable earlier intervention, improve patient safety during anti-thrombotic treatments, and enhance overall cardiovascular health outcomes.

By addressing the global challenge of thrombosis—a leading cause of death and disability—the company aims to provide a reliable solution for early, preventative monitoring. Their work supports the goal of shifting from reactive treatment to proactive, evidence-based health management. The startup has gained recognition through various accolades and support programs, including grants from the Hong Kong Science and Technology Parks Corporation (HKSTP) Incu-Bio Programme, selection by Venture Kick, and winning the first prize at the 2025 International IntelliSense InnovateX Contest. Headquartered in Basel, Switzerland, AiMorphous Health is actively working to bring its diagnostic solutions from development into clinical practice.